Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study

Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives, but also to society and have the potential to involve high costs. To provide more information on the economic burden of preventable...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Value in health Ročník 14; číslo 1; s. 34 - 40
Hlavní autoři:	Leendertse, Anne J., Van Den Bemt, Patricia M.L.A., Poolman, J. Bart, Stoker, Lennart J., Egberts, Antoine C.G., Postma, Maarten J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 2011
Témata:	Adult Adverse drug event Aged Avoidable Burden Case-Control Studies Cost analysis Cost of Illness Direct costs Direct Service Costs Drug-Related Side Effects and Adverse Reactions - economics Female Health Care Costs Health costs Hospitalization Hospitals Humans Internal Medicine Male Medication Errors - economics Middle Aged Models, Econometric Netherlands Patient Admission - economics Patient Admission - statistics & numerical data Pharmacy Productivity costs Prospective Studies Public Health Risk Factors Netherlands Health care costs Direct costs Productivity costs Adverse drug event Pharmacy
ISSN:	1098-3015, 1524-4733, 1524-4733
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives, but also to society and have the potential to involve high costs. To provide more information on the economic burden of preventable adverse drug events of outpatients, we performed a cost study on the data collected in the Hospital Admissions Related to Medication (HARM) study. In this study we examined the frequency, preventability, and risk factors for hospital admissions related to medication. The average costs for a preventable medication-related hospital admission were calculated by summing the direct medical costs and the production losses of all the preventable admissions, taking into account the different types of hospitals (academic and general) and the age of the admitted patients. The average medical costs for one preventable medication-related hospital admission were €5461. The average production loss costs for one admission were €1712 for a person younger than 65 years of age. Combining the medical costs and the costs of production losses resulted in average costs of €6009 for one, potentially preventable, medication-related hospital admission for all ages. The costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs and hospital admissions may be cost-effective or even cost saving.
AbstractList	Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives, but also to society and have the potential to involve high costs. To provide more information on the economic burden of preventable adverse drug events of outpatients, we performed a cost study on the data collected in the Hospital Admissions Related to Medication (HARM) study. In this study we examined the frequency, preventability, and risk factors for hospital admissions related to medication. The average costs for a preventable medication-related hospital admission were calculated by summing the direct medical costs and the production losses of all the preventable admissions, taking into account the different types of hospitals (academic and general) and the age of the admitted patients. The average medical costs for one preventable medication-related hospital admission were €5461. The average production loss costs for one admission were €1712 for a person younger than 65 years of age. Combining the medical costs and the costs of production losses resulted in average costs of €6009 for one, potentially preventable, medication-related hospital admission for all ages. The costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs and hospital admissions may be cost-effective or even cost saving. AbstractObjectiveAdverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives, but also to society and have the potential to involve high costs. To provide more information on the economic burden of preventable adverse drug events of outpatients, we performed a cost study on the data collected in the Hospital Admissions Related to Medication (HARM) study. In this study we examined the frequency, preventability, and risk factors for hospital admissions related to medication. MethodsThe average costs for a preventable medication-related hospital admission were calculated by summing the direct medical costs and the production losses of all the preventable admissions, taking into account the different types of hospitals (academic and general) and the age of the admitted patients. ResultsThe average medical costs for one preventable medication-related hospital admission were €5461. The average production loss costs for one admission were €1712 for a person younger than 65 years of age. Combining the medical costs and the costs of production losses resulted in average costs of €6009 for one, potentially preventable, medication-related hospital admission for all ages. ConclusionsThe costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs and hospital admissions may be cost-effective or even cost saving. Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives, but also to society and have the potential to involve high costs. To provide more information on the economic burden of preventable adverse drug events of outpatients, we performed a cost study on the data collected in the Hospital Admissions Related to Medication (HARM) study. In this study we examined the frequency, preventability, and risk factors for hospital admissions related to medication.OBJECTIVEAdverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives, but also to society and have the potential to involve high costs. To provide more information on the economic burden of preventable adverse drug events of outpatients, we performed a cost study on the data collected in the Hospital Admissions Related to Medication (HARM) study. In this study we examined the frequency, preventability, and risk factors for hospital admissions related to medication.The average costs for a preventable medication-related hospital admission were calculated by summing the direct medical costs and the production losses of all the preventable admissions, taking into account the different types of hospitals (academic and general) and the age of the admitted patients.METHODSThe average costs for a preventable medication-related hospital admission were calculated by summing the direct medical costs and the production losses of all the preventable admissions, taking into account the different types of hospitals (academic and general) and the age of the admitted patients.The average medical costs for one preventable medication-related hospital admission were €5461. The average production loss costs for one admission were €1712 for a person younger than 65 years of age. Combining the medical costs and the costs of production losses resulted in average costs of €6009 for one, potentially preventable, medication-related hospital admission for all ages.RESULTSThe average medical costs for one preventable medication-related hospital admission were €5461. The average production loss costs for one admission were €1712 for a person younger than 65 years of age. Combining the medical costs and the costs of production losses resulted in average costs of €6009 for one, potentially preventable, medication-related hospital admission for all ages.The costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs and hospital admissions may be cost-effective or even cost saving.CONCLUSIONSThe costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs and hospital admissions may be cost-effective or even cost saving. Objective: Adverse drug events (ADEs) can cause serious harm to patients & can lead to hospitalization or even death. ADEs are a burden not only to patients & their relatives, but also to society & have the potential to involve high costs. To provide more information on the economic burden of preventable adverse drug events of outpatients, we performed a cost study on the data collected in the Hospital Admissions Related to Medication (HARM) study. In this study we examined the frequency, preventability, & risk factors for hospital admissions related to medication. Methods: The average costs for a preventable medication-related hospital admission were calculated by summing the direct medical costs & the production losses of all the preventable admissions, taking into account the different types of hospitals (academic & general) & the age of the admitted patients. Results: The average medical costs for one preventable medication-related hospital admission were E5461. The average production loss costs for one admission were E1712 for a person younger than 65 years of age. Combining the medical costs & the costs of production losses resulted in average costs of E6009 for one, potentially preventable, medication-related hospital admission for all ages. Conclusions: The costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs & hospital admissions may be cost-effective or even cost saving. Adapted from the source document.
Author	Poolman, J. Bart Postma, Maarten J. Van Den Bemt, Patricia M.L.A. Leendertse, Anne J. Egberts, Antoine C.G. Stoker, Lennart J.
Author_xml	– sequence: 1 givenname: Anne J. surname: Leendertse fullname: Leendertse, Anne J. organization: Utrecht Institute for Pharmaceutical Sciences (UIPS), Division Pharmacoepidemiology & Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands – sequence: 2 givenname: Patricia M.L.A. surname: Van Den Bemt fullname: Van Den Bemt, Patricia M.L.A. email: P.vandenbemt@uu.nl organization: Utrecht Institute for Pharmaceutical Sciences (UIPS), Division Pharmacoepidemiology & Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands – sequence: 3 givenname: J. Bart surname: Poolman fullname: Poolman, J. Bart organization: Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands – sequence: 4 givenname: Lennart J. surname: Stoker fullname: Stoker, Lennart J. organization: Department of Clinical Pharmacy, Altrecht Institute for Mental Health Care, Den Dolder, The Netherlands – sequence: 5 givenname: Antoine C.G. surname: Egberts fullname: Egberts, Antoine C.G. organization: Utrecht Institute for Pharmaceutical Sciences (UIPS), Division Pharmacoepidemiology & Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands – sequence: 6 givenname: Maarten J. surname: Postma fullname: Postma, Maarten J. organization: Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/21211484$$D View this record in MEDLINE/PubMed
BookMark	eNqFkktv1DAUhS1URB_wB1gg74BFBj8zdoWQqhFQpCIQjyWyPM6N6uCJB9sZaf49DlNYVKJdxbk-59o-3z1FR2McAaGnlCwooe2rYTHsbFgw8qewIEw8QCdUMtGIJedHdU20ajih8hid5jwQQlrO5CN0zCijVChxgn58TrCDsdh1AHwd89YXG7DtNj5nH8eMEwRboMMl4g103tlSy_jF5cWXjy_P8Srmgu1owz77jGOPyzXgeQ_nMnX7x-hhb0OGJzffM_T93dtvq8vm6tP7D6uLq8ZJviwNMKcVkE72VgjXSgGMaylbrWhH13rJme6lsFJIzWj91WtOuXZEM9Xblmh-hp4f-m5T_DVBLqbe30EIdoQ4ZaNaJjVVrbpfyZgmXC3bqnx2o5zW9eVmm_zGpr35m10VsIPApZhzgv6fhBIzAzKDmQGZGdBcq4CqSd0yuZr4nGlJ1oe7ra8PVqhJ7jwkk52H0VUqCVwxXfR329_csrvgxwo0_IQ95CFOqXLMhprMDDFf5-GZZ4fWsSFMstrg_P8N7jv9N3DH0PA
CitedBy_id	crossref_primary_10_1080_14740338_2018_1491547 crossref_primary_10_1111_bcp_13012 crossref_primary_10_1186_s12911_021_01659_8 crossref_primary_10_3389_fpubh_2022_967227 crossref_primary_10_1136_bmjopen_2021_052755 crossref_primary_10_1371_journal_pone_0190298 crossref_primary_10_1007_s40744_024_00692_z crossref_primary_10_1111_bcp_14345 crossref_primary_10_1136_bmjopen_2014_005232 crossref_primary_10_1186_s41927_023_00326_x crossref_primary_10_1136_bmjopen_2014_007488 crossref_primary_10_1136_bmjopen_2018_023377 crossref_primary_10_1007_s40266_016_0361_6 crossref_primary_10_1002_pds_3663 crossref_primary_10_1177_20503121221112485 crossref_primary_10_1038_s41598_022_21515_7 crossref_primary_10_1016_j_ijmedinf_2014_05_003 crossref_primary_10_1111_jphs_12186 crossref_primary_10_3390_pharmacy5020027 crossref_primary_10_3390_pharmacy12040108 crossref_primary_10_1186_s12913_022_07752_6 crossref_primary_10_1007_s40264_018_0737_0 crossref_primary_10_1007_s11096_020_01186_y crossref_primary_10_2196_57697 crossref_primary_10_2196_humanfactors_9891 crossref_primary_10_3389_fpubh_2022_987526 crossref_primary_10_1016_j_sapharm_2018_01_009 crossref_primary_10_1186_s12913_024_11346_9 crossref_primary_10_1111_jgs_19216 crossref_primary_10_1097_PTS_0b013e31828bf5cb crossref_primary_10_1111_jgs_14312 crossref_primary_10_1136_ejhpharm_2015_000868 crossref_primary_10_2196_45086 crossref_primary_10_1136_bmjoq_2023_002570 crossref_primary_10_1111_bcp_13716 crossref_primary_10_1111_jgs_14518 crossref_primary_10_1186_s40545_020_00279_3 crossref_primary_10_1590_1516_3180_2020_0532_02112020 crossref_primary_10_1097_PTS_0000000000000106 crossref_primary_10_2217_pgs_14_44 crossref_primary_10_1016_j_jval_2018_05_007 crossref_primary_10_1111_bcp_14560 crossref_primary_10_3390_genes10060416 crossref_primary_10_1080_20523211_2025_2450593 crossref_primary_10_1016_j_pec_2011_04_038 crossref_primary_10_3390_pharmacy9010046 crossref_primary_10_3389_fphar_2021_761607 crossref_primary_10_1002_sd_2238 crossref_primary_10_1007_s00228_023_03552_x crossref_primary_10_1093_eurpub_ckw021 crossref_primary_10_1080_20523211_2025_2557876 crossref_primary_10_1111_jgs_14007 crossref_primary_10_1136_bmjopen_2015_011007 crossref_primary_10_1016_j_ijmedinf_2024_105398 crossref_primary_10_1136_bmjoq_2017_000303 crossref_primary_10_1111_ajag_12975 crossref_primary_10_1007_s40264_021_01144_1 crossref_primary_10_2147_DHPS_S455990 crossref_primary_10_2196_64446 crossref_primary_10_1093_eurpub_cku037 crossref_primary_10_1177_2042098618754482 crossref_primary_10_1007_s11096_020_01040_1 crossref_primary_10_1186_s12913_022_07583_5 crossref_primary_10_3389_fphar_2023_1149500 crossref_primary_10_1111_bcp_15207 crossref_primary_10_1007_s40266_018_00635_8 crossref_primary_10_14528_snr_2016_50_1_69 crossref_primary_10_1016_j_jamda_2015_06_019 crossref_primary_10_1371_journal_pone_0321118 crossref_primary_10_36290_vnl_2018_148 crossref_primary_10_1177_2042098616675851 crossref_primary_10_1016_j_jamda_2022_11_011 crossref_primary_10_1017_S1041610217001442 crossref_primary_10_1136_bmjopen_2023_078890 crossref_primary_10_1002_prp2_641 crossref_primary_10_1016_j_ijpharm_2016_05_001 crossref_primary_10_1186_s12913_020_5056_3 crossref_primary_10_6061_clinics_2014_03_03 crossref_primary_10_1097_PTS_0000000000000206 crossref_primary_10_1007_s00228_019_02630_3 crossref_primary_10_1159_000543680 crossref_primary_10_1007_s11096_015_0194_0
Cites_doi	10.2165/00019053-200220070-00002 10.1186/1472-6963-9-27 10.1185/03007990903400071 10.1046/j.1365-2125.1998.00667.x 10.2165/00019053-200927010-00003 10.1177/106002808401800117 10.1016/0277-9536(92)90131-9 10.1186/ar2577 10.1093/ajhp/58.12.1126 10.1001/jama.1979.03300070019017 10.1016/S0953-6205(01)00159-5 10.1002/hec.948 10.1001/jama.1997.03540280045032 10.3310/hta12130 10.5694/j.1326-5377.1996.tb122235.x 10.1016/0002-9343(88)90250-1 10.1056/NEJM199803123381105 10.1136/bmj.320.7246.1373 10.1136/bmj.329.7456.15 10.1016/0167-6296(94)00044-5 10.1002/14651858.CD003448.pub2 10.1176/ajp.137.9.1093 10.2165/00019053-200321090-00002 10.1186/1472-6904-7-8 10.3310/hta10380 10.3310/hta4120 10.1002/pds.871 10.1056/NEJM199803123381104
ContentType	Journal Article
Copyright	2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – notice: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – notice: Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7QJ
DOI	10.1016/j.jval.2010.10.024
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Applied Social Sciences Index & Abstracts (ASSIA)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA)
DatabaseTitleList	MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology Public Health
EISSN	1524-4733
EndPage	40
ExternalDocumentID	21211484 10_1016_j_jval_2010_10_024 S1098301510000252 1_s2_0_S1098301510000252
Genre	Research Support, Non-U.S. Gov't Multicenter Study Journal Article
GeographicLocations	Netherlands
GeographicLocations_xml	– name: Netherlands
GrantInformation_xml	– fundername: The Dutch Order of Medical Specialists
GroupedDBID	--- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6PF 7-5 7PT 8-1 8P~ 8UM AAEDT AAEDW AAFJI AAFWJ AAIKJ AAKOC AALRI AAMMB AAOAW AAPFB AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACLOT ACPRK ACRLP ACRPL ACUHS ACVFH ACXQS ADBBV ADCNI ADEZE ADFHU ADMUD ADNMO ADVLN AEBSH AEFGJ AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AEYQN AFBPY AFEBI AFJKZ AFPUW AFRHN AFTJW AFXIZ AFZJQ AGHFR AGQPQ AGTHC AGUBO AGXDD AGYEJ AIDQK AIDYY AIEXJ AIGII AIIAU AIIUN AIKHN AITUG AJAOE AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EFKBS EFLBG EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB KOM LH4 M41 MO0 N9A O-L O9- OAUVE OIG OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SV3 T5K TEORI TUS W99 WIN WYUIH XG1 YFH Z5R ~G- ~HD 0SF 6I. AACTN AAFTH AAHHS ABVKL ACCFJ AEEZP AEQDE AFCTW AFKWA AIWBW AJBDE AJOXV AMFUW NCXOZ RIG SUPJJ AAIAV ABLVK ABYKQ AJBFU AKYCK IXIXF LCYCR AAYXX ALUQN CITATION O8X AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 7QJ
ID	FETCH-LOGICAL-c537t-e2c98e0d5fa44c654e239556981d1b97329f54a5459219739b3139c0928fa6093
ISICitedReferencesCount	89
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000299039700005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-3015 1524-4733
IngestDate	Sat Sep 27 22:53:58 EDT 2025 Sun Sep 28 14:00:25 EDT 2025 Mon Jul 21 05:48:25 EDT 2025 Sat Nov 29 05:41:31 EST 2025 Tue Nov 18 22:17:42 EST 2025 Fri Feb 23 02:30:32 EST 2024 Sun Feb 23 10:19:11 EST 2025 Tue Oct 14 19:38:40 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Health care costs Direct costs Productivity costs Adverse drug event Pharmacy
Language	English
License	http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 https://www.elsevier.com/open-access/userlicense/1.0 Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c537t-e2c98e0d5fa44c654e239556981d1b97329f54a5459219739b3139c0928fa6093
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.clinicalkey.com/#!/content/1-s2.0-S1098301510000252
PMID	21211484
PQID	822903876
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_862591868 proquest_miscellaneous_822903876 pubmed_primary_21211484 crossref_primary_10_1016_j_jval_2010_10_024 crossref_citationtrail_10_1016_j_jval_2010_10_024 elsevier_sciencedirect_doi_10_1016_j_jval_2010_10_024 elsevier_clinicalkeyesjournals_1_s2_0_S1098301510000252 elsevier_clinicalkey_doi_10_1016_j_jval_2010_10_024
PublicationCentury	2000
PublicationDate	2011 2011-01-00 2011-Jan 20110101
PublicationDateYYYYMMDD	2011-01-01
PublicationDate_xml	– year: 2011 text: 2011
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Value in health
PublicationTitleAlternate	Value Health
PublicationYear	2011
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Leendertse, Egberts, Stoker, van den Bemt (bib2) 2008; 168 Zermansky, Silcock (bib26) 2009; 27 Hawkey, Karrasch, Szczepanski (bib28) 1998; 338 Bates, Spell, Cullen (bib3) 1997; 277 Pirmohamed, James, Meakin (bib1) 2004; 329 Ramesh, Pandit, Parthasarathi (bib14) 2003; 12 Kramer, Leventhal, Hutchinson, Feinstein (bib16) 1979; 242 Schumock, Thornton (bib17) 1992; 27 Patel, Kedia, Bajpai (bib5) 2007; 7 Vonkeman, Braakman-Jansen, Klok (bib30) 2008; 10 Brown, Hooper, Elliott (bib29) 2006; 10 Treasury (bib10) Bloom (bib13) 1988; 84 Salem, Keane, Williams (bib24) 1984; 18 Yeomans, Tulassay, Juhasz (bib27) 1998; 338 Tunis, Minshall (bib33) 2010; 26 Miles, Fellowes, Goodman, Wilkinson (bib34) 2006; 18 Oostenbrink, Koopmanschap, Rutten (bib19) 2002; 20 Koopmanschap, van Ineveld (bib21) 1992; 34 Moore, Lecointre, Noblet (bib15) 1998; 45 (bib20) 1999 Giesbers (bib6) June 2006 Wasserfallen, Livio, Buclin (bib11) 2001; 12 Oostenbrink, Bouwmans, Koopmanschap, Rutten (bib18) 2004 Senst, Achusim, Genest (bib8) 2001; 58 Coster, Gulliford, Seed, Powrie, Swaminathan (bib31) 2000; 4 Mihaylov, Stark, McColl (bib35) 2008; 12 Van Hilten, Mares (bib7) 2007 Koopmanschap, Rutten, van Ineveld (bib23) 1995; 14 Jacob-Tacken, Koopmanschap, Meerding, Severens (bib22) 2005; 14 Rodriguez-Monguio, Otero, Rovira (bib9) 2003; 21 Gray, Raikou, McGuire (bib32) 2000; 320 Hoonhout, de Bruijne, Wagner (bib4) 2009; 9 Stewart, Sprinker, Adams (bib25) 1980; 137 Dartnell, Anderson, Chohan (bib12) 1996; 1634 Koopmanschap (10.1016/j.jval.2010.10.024_bib21) 1992; 34 Brown (10.1016/j.jval.2010.10.024_bib29) 2006; 10 Stewart (10.1016/j.jval.2010.10.024_bib25) 1980; 137 Wasserfallen (10.1016/j.jval.2010.10.024_bib11) 2001; 12 Salem (10.1016/j.jval.2010.10.024_bib24) 1984; 18 Bates (10.1016/j.jval.2010.10.024_bib3) 1997; 277 Hawkey (10.1016/j.jval.2010.10.024_bib28) 1998; 338 Kramer (10.1016/j.jval.2010.10.024_bib16) 1979; 242 Tunis (10.1016/j.jval.2010.10.024_bib33) 2010; 26 Leendertse (10.1016/j.jval.2010.10.024_bib2) 2008; 168 Koopmanschap (10.1016/j.jval.2010.10.024_bib23) 1995; 14 Giesbers (10.1016/j.jval.2010.10.024_bib6) 2006 Gray (10.1016/j.jval.2010.10.024_bib32) 2000; 320 Dartnell (10.1016/j.jval.2010.10.024_bib12) 1996; 1634 Patel (10.1016/j.jval.2010.10.024_bib5) 2007; 7 Vonkeman (10.1016/j.jval.2010.10.024_bib30) 2008; 10 Mihaylov (10.1016/j.jval.2010.10.024_bib35) 2008; 12 Oostenbrink (10.1016/j.jval.2010.10.024_bib18) 2004 Rodriguez-Monguio (10.1016/j.jval.2010.10.024_bib9) 2003; 21 Pirmohamed (10.1016/j.jval.2010.10.024_bib1) 2004; 329 Senst (10.1016/j.jval.2010.10.024_bib8) 2001; 58 Bloom (10.1016/j.jval.2010.10.024_bib13) 1988; 84 Oostenbrink (10.1016/j.jval.2010.10.024_bib19) 2002; 20 Jacob-Tacken (10.1016/j.jval.2010.10.024_bib22) 2005; 14 Moore (10.1016/j.jval.2010.10.024_bib15) 1998; 45 Treasury (10.1016/j.jval.2010.10.024_bib10) Zermansky (10.1016/j.jval.2010.10.024_bib26) 2009; 27 Coster (10.1016/j.jval.2010.10.024_bib31) 2000; 4 Miles (10.1016/j.jval.2010.10.024_bib34) 2006; 18 Van Hilten (10.1016/j.jval.2010.10.024_bib7) 2007 Yeomans (10.1016/j.jval.2010.10.024_bib27) 1998; 338 Schumock (10.1016/j.jval.2010.10.024_bib17) 1992; 27 Ramesh (10.1016/j.jval.2010.10.024_bib14) 2003; 12 (10.1016/j.jval.2010.10.024_bib20) 1999 Hoonhout (10.1016/j.jval.2010.10.024_bib4) 2009; 9
References_xml	– volume: 277 start-page: 307 year: 1997 end-page: 311 ident: bib3 article-title: The costs of adverse drug events in hospitalized patients publication-title: JAMA – volume: 14 start-page: 171 year: 1995 end-page: 189 ident: bib23 article-title: The friction cost method for measuring indirect costs of disease publication-title: J Health Econ – volume: 137 start-page: 1093 year: 1980 end-page: 1095 ident: bib25 article-title: Drug-related admissions to an inpatient psychiatric unit publication-title: Am J Psychiatry – year: June 2006 ident: bib6 article-title: Hospital bed capacity 2003 publication-title: Volksgezondheid Toekomst Verkenning, Nationale Atlas Volksgezondheid – volume: 1634 start-page: 659 year: 1996 end-page: 662 ident: bib12 article-title: Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs publication-title: Med J Aust – volume: 242 start-page: 623 year: 1979 end-page: 631 ident: bib16 article-title: An algorithm for the operational assessment of adverse drug reactions, I: background, description, and instructions for use publication-title: JAMA – volume: 12 start-page: 442 year: 2001 end-page: 447 ident: bib11 article-title: Rate, type and cost of adverse drug reactions in emergency department admissions publication-title: Eur J Intern Med – ident: bib10 article-title: Table 5.4 public sector current and capital expenditure on services by function, 2003-04 to 20070-08 – volume: 14 start-page: 435 year: 2005 end-page: 443 ident: bib22 article-title: Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes publication-title: Health Econ – volume: 10 start-page: R144 year: 2008 ident: bib30 article-title: Incremental cost effectiveness of proton pump inhibitors for the prevention of nonsteroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study publication-title: Arthritis Res Ther – volume: 12 start-page: iii year: 2008 end-page: iv ident: bib35 article-title: Stepped treatment of older adults on laxatives publication-title: Health Technol Assess – volume: 338 start-page: 727 year: 1998 end-page: 734 ident: bib28 article-title: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs publication-title: N Engl J Med – volume: 320 start-page: 1373 year: 2000 end-page: 1378 ident: bib32 article-title: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) publication-title: BMJ – volume: 27 start-page: 538 year: 1992 ident: bib17 article-title: Focusing on the preventability of adverse drug reactions publication-title: Hosp Pharm – volume: 329 start-page: 15 year: 2004 end-page: 19 ident: bib1 article-title: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients publication-title: BMJ – volume: 10 start-page: 1 year: 2006 end-page: 183 ident: bib29 article-title: A comparison of the cost-effectiveness of five strategies for the prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling publication-title: Health Technol Assess – volume: 58 start-page: 1126 year: 2001 end-page: 1132 ident: bib8 article-title: Practical approach to determining costs and frequency of adverse drug events in a health care network publication-title: Am J Health Syst Pharm – volume: 20 start-page: 443 year: 2002 end-page: 454 ident: bib19 article-title: Standardisation of costs: the Dutch Manual for Costing in economic evaluations publication-title: Pharmacoeconomics – volume: 338 start-page: 719 year: 1998 end-page: 726 ident: bib27 article-title: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs publication-title: N Engl J Med – volume: 18 year: 2006 ident: bib34 article-title: Laxatives for the management of constipation in palliative care patients publication-title: Cochrane Database Syst Rev – volume: 18 start-page: 74 year: 1984 end-page: 76 ident: bib24 article-title: Drug-related admissions to a Veterans' Administration psychiatric unit publication-title: Drug Intell Clin Pharm – volume: 4 start-page: 1 year: 2000 end-page: 93 ident: bib31 article-title: Monitoring blood glucose control in diabetes mellitus: a systematic review publication-title: Health Technol Assess – volume: 26 start-page: 151 year: 2010 end-page: 162 ident: bib33 article-title: Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the United States publication-title: Curr Med Res Opin – volume: 7 start-page: 8 year: 2007 ident: bib5 article-title: Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study publication-title: BMC Clin Pharmacol – volume: 12 start-page: 687 year: 2003 end-page: 692 ident: bib14 article-title: Adverse drug reactions in a south Indian hospital—their severity and cost involved publication-title: Pharmacoepidemiol Drug Saf – volume: 27 start-page: 11 year: 2009 end-page: 24 ident: bib26 article-title: Is medication review by primary-care pharmacists for older people cost effective? publication-title: Pharmacoeconomics – volume: 84 start-page: 20 year: 1988 end-page: 24 ident: bib13 article-title: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis publication-title: Am J Med – volume: 45 start-page: 301 year: 1998 end-page: 308 ident: bib15 article-title: Frequency and cost of serious adverse drug reactions in a department of general medicine publication-title: Br J Clin Pharmacol – volume: 168 start-page: 1890 year: 2008 end-page: 1896 ident: bib2 article-title: Frequency of and risk factors for preventable medication-related hospital admissions in The Netherlands publication-title: Arch Intern Med – volume: 34 start-page: 1005 year: 1992 end-page: 1010 ident: bib21 article-title: Towards a new approach for estimating indirect costs of disease publication-title: Soc Sci Med – year: 2007 ident: bib7 article-title: Figures in Health and Healthcare 2007 – volume: 9 start-page: 27 year: 2009 ident: bib4 article-title: Direct medical costs of adverse events in Dutch hospitals publication-title: BMC Health Serv Res – year: 1999 ident: bib20 article-title: Richtlijnen voor farmaco-economisch onderzoek – volume: 21 start-page: 623 year: 2003 end-page: 650 ident: bib9 article-title: Assessing the economic impact of adverse drug effects publication-title: Pharmacoeconomics – year: 2004 ident: bib18 article-title: Dutch Guidelines for Pharmacoeconomic Research – volume: 20 start-page: 443 year: 2002 ident: 10.1016/j.jval.2010.10.024_bib19 article-title: Standardisation of costs: the Dutch Manual for Costing in economic evaluations publication-title: Pharmacoeconomics doi: 10.2165/00019053-200220070-00002 – volume: 9 start-page: 27 year: 2009 ident: 10.1016/j.jval.2010.10.024_bib4 article-title: Direct medical costs of adverse events in Dutch hospitals publication-title: BMC Health Serv Res doi: 10.1186/1472-6963-9-27 – volume: 26 start-page: 151 year: 2010 ident: 10.1016/j.jval.2010.10.024_bib33 article-title: Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the United States publication-title: Curr Med Res Opin doi: 10.1185/03007990903400071 – volume: 45 start-page: 301 year: 1998 ident: 10.1016/j.jval.2010.10.024_bib15 article-title: Frequency and cost of serious adverse drug reactions in a department of general medicine publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1998.00667.x – volume: 27 start-page: 11 year: 2009 ident: 10.1016/j.jval.2010.10.024_bib26 article-title: Is medication review by primary-care pharmacists for older people cost effective? publication-title: Pharmacoeconomics doi: 10.2165/00019053-200927010-00003 – volume: 18 start-page: 74 year: 1984 ident: 10.1016/j.jval.2010.10.024_bib24 article-title: Drug-related admissions to a Veterans' Administration psychiatric unit publication-title: Drug Intell Clin Pharm doi: 10.1177/106002808401800117 – year: 1999 ident: 10.1016/j.jval.2010.10.024_bib20 – volume: 34 start-page: 1005 year: 1992 ident: 10.1016/j.jval.2010.10.024_bib21 article-title: Towards a new approach for estimating indirect costs of disease publication-title: Soc Sci Med doi: 10.1016/0277-9536(92)90131-9 – volume: 10 start-page: R144 year: 2008 ident: 10.1016/j.jval.2010.10.024_bib30 article-title: Incremental cost effectiveness of proton pump inhibitors for the prevention of nonsteroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study publication-title: Arthritis Res Ther doi: 10.1186/ar2577 – volume: 58 start-page: 1126 year: 2001 ident: 10.1016/j.jval.2010.10.024_bib8 article-title: Practical approach to determining costs and frequency of adverse drug events in a health care network publication-title: Am J Health Syst Pharm doi: 10.1093/ajhp/58.12.1126 – ident: 10.1016/j.jval.2010.10.024_bib10 – volume: 242 start-page: 623 year: 1979 ident: 10.1016/j.jval.2010.10.024_bib16 article-title: An algorithm for the operational assessment of adverse drug reactions, I: background, description, and instructions for use publication-title: JAMA doi: 10.1001/jama.1979.03300070019017 – volume: 12 start-page: 442 year: 2001 ident: 10.1016/j.jval.2010.10.024_bib11 article-title: Rate, type and cost of adverse drug reactions in emergency department admissions publication-title: Eur J Intern Med doi: 10.1016/S0953-6205(01)00159-5 – volume: 14 start-page: 435 year: 2005 ident: 10.1016/j.jval.2010.10.024_bib22 article-title: Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes publication-title: Health Econ doi: 10.1002/hec.948 – volume: 277 start-page: 307 year: 1997 ident: 10.1016/j.jval.2010.10.024_bib3 article-title: The costs of adverse drug events in hospitalized patients publication-title: JAMA doi: 10.1001/jama.1997.03540280045032 – year: 2004 ident: 10.1016/j.jval.2010.10.024_bib18 – year: 2006 ident: 10.1016/j.jval.2010.10.024_bib6 article-title: Hospital bed capacity 2003 – volume: 12 start-page: iii year: 2008 ident: 10.1016/j.jval.2010.10.024_bib35 article-title: Stepped treatment of older adults on laxatives publication-title: Health Technol Assess doi: 10.3310/hta12130 – volume: 1634 start-page: 659 year: 1996 ident: 10.1016/j.jval.2010.10.024_bib12 article-title: Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs publication-title: Med J Aust doi: 10.5694/j.1326-5377.1996.tb122235.x – volume: 84 start-page: 20 issue: Suppl. 2A year: 1988 ident: 10.1016/j.jval.2010.10.024_bib13 article-title: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis publication-title: Am J Med doi: 10.1016/0002-9343(88)90250-1 – volume: 338 start-page: 727 year: 1998 ident: 10.1016/j.jval.2010.10.024_bib28 article-title: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs publication-title: N Engl J Med doi: 10.1056/NEJM199803123381105 – volume: 320 start-page: 1373 year: 2000 ident: 10.1016/j.jval.2010.10.024_bib32 article-title: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) publication-title: BMJ doi: 10.1136/bmj.320.7246.1373 – volume: 329 start-page: 15 year: 2004 ident: 10.1016/j.jval.2010.10.024_bib1 article-title: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients publication-title: BMJ doi: 10.1136/bmj.329.7456.15 – volume: 14 start-page: 171 year: 1995 ident: 10.1016/j.jval.2010.10.024_bib23 article-title: The friction cost method for measuring indirect costs of disease publication-title: J Health Econ doi: 10.1016/0167-6296(94)00044-5 – year: 2007 ident: 10.1016/j.jval.2010.10.024_bib7 – volume: 18 year: 2006 ident: 10.1016/j.jval.2010.10.024_bib34 article-title: Laxatives for the management of constipation in palliative care patients publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD003448.pub2 – volume: 168 start-page: 1890 year: 2008 ident: 10.1016/j.jval.2010.10.024_bib2 article-title: Frequency of and risk factors for preventable medication-related hospital admissions in The Netherlands publication-title: Arch Intern Med – volume: 137 start-page: 1093 year: 1980 ident: 10.1016/j.jval.2010.10.024_bib25 article-title: Drug-related admissions to an inpatient psychiatric unit publication-title: Am J Psychiatry doi: 10.1176/ajp.137.9.1093 – volume: 21 start-page: 623 year: 2003 ident: 10.1016/j.jval.2010.10.024_bib9 article-title: Assessing the economic impact of adverse drug effects publication-title: Pharmacoeconomics doi: 10.2165/00019053-200321090-00002 – volume: 27 start-page: 538 year: 1992 ident: 10.1016/j.jval.2010.10.024_bib17 article-title: Focusing on the preventability of adverse drug reactions publication-title: Hosp Pharm – volume: 7 start-page: 8 year: 2007 ident: 10.1016/j.jval.2010.10.024_bib5 article-title: Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study publication-title: BMC Clin Pharmacol doi: 10.1186/1472-6904-7-8 – volume: 10 start-page: 1 year: 2006 ident: 10.1016/j.jval.2010.10.024_bib29 article-title: A comparison of the cost-effectiveness of five strategies for the prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling publication-title: Health Technol Assess doi: 10.3310/hta10380 – volume: 4 start-page: 1 year: 2000 ident: 10.1016/j.jval.2010.10.024_bib31 article-title: Monitoring blood glucose control in diabetes mellitus: a systematic review publication-title: Health Technol Assess doi: 10.3310/hta4120 – volume: 12 start-page: 687 year: 2003 ident: 10.1016/j.jval.2010.10.024_bib14 article-title: Adverse drug reactions in a south Indian hospital—their severity and cost involved publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.871 – volume: 338 start-page: 719 year: 1998 ident: 10.1016/j.jval.2010.10.024_bib27 article-title: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs publication-title: N Engl J Med doi: 10.1056/NEJM199803123381104
SSID	ssj0006325
Score	2.2970486
Snippet	Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their... AbstractObjectiveAdverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to... Objective: Adverse drug events (ADEs) can cause serious harm to patients & can lead to hospitalization or even death. ADEs are a burden not only to patients &...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	34
SubjectTerms	Adult Adverse drug event Aged Avoidable Burden Case-Control Studies Cost analysis Cost of Illness Direct costs Direct Service Costs Drug-Related Side Effects and Adverse Reactions - economics Female Health Care Costs Health costs Hospitalization Hospitals Humans Internal Medicine Male Medication Errors - economics Middle Aged Models, Econometric Netherlands Patient Admission - economics Patient Admission - statistics & numerical data Pharmacy Productivity costs Prospective Studies Public Health Risk Factors
Title	Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1098301510000252 https://www.clinicalkey.es/playcontent/1-s2.0-S1098301510000252 https://dx.doi.org/10.1016/j.jval.2010.10.024 https://www.ncbi.nlm.nih.gov/pubmed/21211484 https://www.proquest.com/docview/822903876 https://www.proquest.com/docview/862591868
Volume	14
WOSCitedRecordID	wos000299039700005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1524-4733 dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0006325 issn: 1098-3015 databaseCode: AIEXJ dateStart: 19980501 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGhxAvCMatXCY_wATqUqWJncS8lTE0qnaqWJn6Mllp4ohVJZmWdtp-CX-X41vSUVYuElIVVbEdVzlffY6Pv3MOQq86bJLGTPhOmAnmkESEThxlgSM8N41ApYBSV4HC_fDwMBqP2XBj47uNhbmYhXkeXV6ys_8qargHwpahs38h7uqhcAO-g9DhCmKH6x8J3iRlUiFRX01VkFacgjxLRXpT0StgZoLRqQ7WLQKig-7nwWuPSR_BXlFK5nmdr0Sap7J9KR2tsWiP49lCJR7REZVLBB8ZNjPXdRu7sJq3em3beAyLygeRt96Lb5okrOoEnMatQbvf7lbdhkUxMw7aXluejFQUnaN5YdggfVAU0GAfnlqHbO1OsyE11xifHZngFFYdem2JJitQ1OutcYRqza3zPq3oBO2emLanIEvN5ZN0Po_UGrDiJR7J2eXk6tTDo6DbN72QsqiBNruf9se9SskHvqrnW_1aE4-lqYM_z3STzXPTnkbZNqP76J7ZlOCuBtMDtCHyLXRnYGgXW2hnqBOcX-3iUR2vV-7iHTysU59fPUQnS-DDFny4Bh824MPzAtfgw28ktN6-wxJ22MIOFxkG2GHZhhXsHqEvH_dHeweOKeDhJNQP5_CHT1gk3JRmMSFJQInwfEZpwGCT1JnIPFEsoyQGI56B4gx9NvFhQ5K4zIuyOHCZ_xg18iIXTxGmfsrAkofnpoQwQeIUbF_oRTLqxuEkaKKOfcU8MdntZZGVGbc0ximXYuFSLPIeiKWJWtWYM53bZW1v30qO26hl0LMcYLZ2VPirUaI0K0bJO7z0uMtXoNdEtBpprGFt5f52RmxhxUG68vwvzkWxKLmq7eCD-bOmi3SHyAoaTfREI7J6M55MBkki8uyf3sNzdFefxsjPC9SYny_ES3Q7uZiflufb6FY4jrbNf-wHpjT1Xg
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preventable+hospital+admissions+related+to+medication+%28HARM%29%3A+Cost+analysis+of+the+HARM+study&rft.jtitle=Value+in+health&rft.au=Leendertse%2C+Anne+J.&rft.au=Van+Den+Bemt%2C+Patricia+M.L.A.&rft.au=Poolman%2C+J.+Bart&rft.au=Stoker%2C+Lennart+J.&rft.date=2011&rft.pub=Elsevier+Inc&rft.issn=1098-3015&rft.volume=14&rft.issue=1&rft.spage=34&rft.epage=40&rft_id=info:doi/10.1016%2Fj.jval.2010.10.024&rft.externalDocID=S1098301510000252
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10983015%2FS1098301510X0002X%2Fcov150h.gif